Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + escitalopram is a combination of two agents used in the context of depression treatment. Curcumin is a natural polyphenolic compound derived from turmeric (Curcuma longa) with pleiotropic pharmacological properties, including anti-inflammatory, antioxidant, and potential antidepressant effects. Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) approved for major depressive disorder and anxiety disorders. The rationale for combining these agents stems from evidence that curcumin may potentiate the antidepressant effect of SSRIs like escitalopram by modulating neurotransmitter systems (serotonin, dopamine, noradrenaline), neuroprogression pathways, hypothalamic-pituitary-adrenal axis disturbances, inflammation/immune responses, oxidative stress pathways, and mitochondrial function. Clinical studies suggest that while the combination may not significantly outperform standard SSRI therapy in all measures, it could offer more rapid symptom relief without additional adverse effects[1][6]. Drug interaction data indicate that curcumin can decrease the metabolism of escitalopram via CYP450 inhibition[3][4][5], potentially increasing its plasma concentration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + escitalopram.